Balinth et al. showed that EZH2 inhibits the tumor suppressor RUNX3, which activates SETDB1 and ΔNp63α, driving an invasive tumor stem cell phenotype, and that the use of an EZH2 inhibitor reactivates RUNX3, thereby reversing this process [139]. Here, EZH2 is linked to neoplasm.